This company has been marked as potentially delisted and may not be actively trading. Zafgen (ZFGN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock ZFGN vs. MBX, RVNC, CKPT, AVTE, TSVT, SLRN, CYBN, BIOA, NLTX, and PROCShould you be buying Zafgen stock or one of its competitors? The main competitors of Zafgen include MBX Biosciences (MBX), Revance Therapeutics (RVNC), Checkpoint Therapeutics (CKPT), Aerovate Therapeutics (AVTE), 2seventy bio (TSVT), Acelyrin (SLRN), Cybin (CYBN), BioAge Labs (BIOA), Neoleukin Therapeutics (NLTX), and Procaps Group (PROC). Zafgen vs. Its Competitors MBX Biosciences Revance Therapeutics Checkpoint Therapeutics Aerovate Therapeutics 2seventy bio Acelyrin Cybin BioAge Labs Neoleukin Therapeutics Procaps Group MBX Biosciences (NYSE:MBX) and Zafgen (NASDAQ:ZFGN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk. Which has preferable earnings and valuation, MBX or ZFGN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMBX BiosciencesN/AN/AN/AN/AN/AZafgenN/AN/A-$45.41M-$1.07-2.99 Does the media prefer MBX or ZFGN? In the previous week, MBX Biosciences had 1 more articles in the media than Zafgen. MarketBeat recorded 1 mentions for MBX Biosciences and 0 mentions for Zafgen. MBX Biosciences' average media sentiment score of 1.91 beat Zafgen's score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the media. Company Overall Sentiment MBX Biosciences Very Positive Zafgen Neutral Is MBX or ZFGN more profitable? MBX Biosciences' return on equity of 0.00% beat Zafgen's return on equity.Company Net Margins Return on Equity Return on Assets MBX BiosciencesN/A N/A N/A Zafgen N/A -51.34%-34.55% Do institutionals & insiders believe in MBX or ZFGN? 70.4% of Zafgen shares are held by institutional investors. 52.2% of MBX Biosciences shares are held by insiders. Comparatively, 14.2% of Zafgen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend MBX or ZFGN? MBX Biosciences presently has a consensus target price of $37.50, indicating a potential upside of 200.60%. Given MBX Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe MBX Biosciences is more favorable than Zafgen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Zafgen 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryMBX Biosciences beats Zafgen on 8 of the 9 factors compared between the two stocks. Get Zafgen News Delivered to You Automatically Sign up to receive the latest news and ratings for ZFGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZFGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZFGN vs. The Competition Export to ExcelMetricZafgenPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$119.90M$812.96M$5.56B$9.05BDividend YieldN/A4.84%5.24%3.99%P/E Ratio-3.331.1519.9620.26Price / SalesN/A230.41419.56119.26Price / CashN/A23.4426.2128.59Price / Book2.376.328.035.65Net Income-$45.41M-$27.99M$3.18B$249.15M Zafgen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZFGNZafgenN/A$3.20+2.9%N/A-57.8%$119.90MN/A-3.3338MBXMBX Biosciences3.2437 of 5 stars$11.71+2.6%$37.50+220.4%N/A$387.72MN/A0.0036RVNCRevance Therapeutics2.762 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500CKPTCheckpoint Therapeutics0.4639 of 5 stars$4.26flat$4.33+1.7%N/A$370.71M$41K-2.3210AVTEAerovate TherapeuticsN/A$9.99+8.7%N/A-80.2%$289.56MN/A-3.3420High Trading VolumeTSVT2seventy bioN/A$5.00flat$5.00N/A$266.15M$48.37M-2.69440SLRNAcelyrinN/A$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135CYBNCybin3.136 of 5 stars$9.03+7.7%$86.00+852.0%N/A$207.79MN/A-2.0650News CoverageAnalyst RevisionHigh Trading VolumeBIOABioAge LabsN/A$4.23+2.4%N/AN/A$151.65MN/A0.00N/ANLTXNeoleukin TherapeuticsN/A$14.95-7.5%N/A-44.2%$140.50MN/A-4.8190High Trading VolumePROCProcaps GroupN/A$0.95-40.3%N/A-62.0%$107.18M$409.92M0.004,900Gap DownHigh Trading Volume Related Companies and Tools Related Companies MBX Alternatives RVNC Alternatives CKPT Alternatives AVTE Alternatives TSVT Alternatives SLRN Alternatives CYBN Alternatives BIOA Alternatives NLTX Alternatives PROC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZFGN) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zafgen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Zafgen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.